• In non-alcoholic fatty liver disease and atherosclerosis, SGC707 inhibits PRMT3 activity, reduces hepatic triglyceride accumulation, affects white adipocyte size, alters plasma bile acid levels and TGR5 activation. Here, GPBAR1 is linked to atherosclerosis.